U.S., June 16 -- ClinicalTrials.gov registry received information related to the study (NCT07647510) titled 'A Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE)' on May 27.

Brief Summary: The purpose of this Phase 3 study is to demonstrate the efficacy, safety, and tolerability of claseprubart in participants with generalized myasthenia gravis (gMG).

Study Start Date: July, 2026

Study Type: INTERVENTIONAL

Condition: Myasthenia Gravis, Generalized

Intervention: DRUG: Claseprubart

IV loading dose on Day 1

DRUG: Placebo

IV infusion on Day 1

COMBINATION_PRODUCT: Claseprubart

Prefilled syringe containing claseprubart for SC administration

COMBINATION_PRODUCT: Placebo

Prefilled syringe cont...